Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Diclofenac improves lidocaine’s analgesic efficacy during benign anorectal surgery

07 Dec 2018

The combination of lidocaine and diclofenac is superior to lidocaine alone at reducing pain during benign anorectal surgery (BARS), a recent study has shown.

Researchers randomly assigned 120 patients undergoing BARS to receive topical treatment of either lidocaine plus diclofenac (n=60; mean age 47.37±11.79 years; 50 percent male) or lidocaine alone (n=60; mean age 47.73±11.79 years; 70 percent male). Treatment was applied every 12 hours for the first 3 postoperative days and once-daily from the fourth to sixth day. Reasons for receiving BARS included haemorrhoids, anal fissures and anal fistulae.

Pain intensity, as measured by the visual analogue scale (VAS), was significantly lower in the first 3 postoperative days in patients who received the combination treatment (7.47±13.09 vs 4.38±6.75; difference, –3.21; 95 percent CI, –5.75 to –0.68; p=0.008). The same was true when analysis was extended to the first 6 days after operation (8.08±14.50 vs 4.26±6.55; difference, –3.92; –6.62 to –1.22; p=0.004).

Moreover, significantly more patients who received both treatments reported pain reduction 9 mm relative to those who received the monotherapy (35 percent vs 18.33 percent; relative risk [RR], 1.91; 1.01–3.60; p=0.03).

Researchers found similar trends for the probability of progressing from high to lower pain levels, according to VAS cutoffs, though values were only of borderline significance (RR, 1.43; 0.98–2.09; p=0.06).

Both treatments were comparatively safe, with no reported cases of associated adverse events for the first 7 postoperative days.

Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
5 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Yesterday
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.